Dosage and administrationCereton has an indication-specific dosing, with the most common regime being 1 capsule thrice daily, preferably after meals.
Side effectsAllergy reactions. In case of nausea due to dofaminergic activation, the dose should be decreased.
Country of Manufacture: Russia
Note: Alpha-GPC works particularly well with racetams, like Piracetam and Aniracetam. These racetams boost acetylcholine receptors in the brain, which means your brain needs to produce more acetylcholine. Alpha-GPC gives your brain the acetylcholine it needs by delivering high amounts of choline.
More information can be found here: https://examine.com/supplements/alpha-gpc/
4-Week Course is 3 boxes of 28 pills - Get it with volume discount!
DescriptionAlpha-GPC was discovered in 1864 by a German chemist Adolph Strecker. Nowadays, it is routinely prescribed by doctors in Europe as a treatment for Alzheimer’s and other degenerative conditions. In body, Alpha-GPC is cleaved into glycerophosphate and free choline. The former is the precursor of phosphatidylcholine, while the latter enhances the synthesis of acetylcholine. Both phosphatidylcholine and acetylcholine are able to improve certain cognitive functions, including memory retention, focus, and neuroplasticity. Cereton ® contains 40.5% of metabolically protected choline and has a dose-dependent effect on the levels of acetylcholine in the brain. Cereton ® has been proven to be efficient when used for:
- Strokes and stroke complications;
- Alzheimer's disease and other types of dementia;
- Traumatic brain injuries;
- Psychoorganic syndrome;
- Various cognitive disorders e.g. disorientation, low motivation, concentration difficulties, etc.
One pack of Cereton ® contains 28 pills, each containing 400 mg of the active ingredient, which is sufficient for an average of 9 - 14 days of use. The drug can be taken for a period of up to 6 months.
Country of Manufacture: Russia
- Lopez et al (1991) Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain https://www.ncbi.nlm.nih.gov/pubmed/1662399
- Schettini et al (1992) Molecular mechanisms mediating the effects of L-alpha-glycerylphosphorylcholine, a new cognition-enhancing drug, on behavioral and biochemical parameters in young and aged rats https://www.ncbi.nlm.nih.gov/pubmed/1409797
- N Maslova, A Pysina (2008) The use of cereton in ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/19431273
- Shmyrev et al (2008) The domestic drug cereton in the treatment of patients in the acute period of ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/19253468
- Builova et al (2009) The use of cereton in the rehabilitation of patients with hemorrhagic stroke https://www.ncbi.nlm.nih.gov/pubmed/19894302
- Levin et al (2009) Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders https://www.ncbi.nlm.nih.gov/pubmed/20032953
- Stulin et al (2009) Choline alphoscerate (ceretone) in the treatment of patients with chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/19708279
- Ismagilov et al (2009) Efficacy of cereton in the acute period of ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/19365389
- N Pizova (2014) The use of cereton in patients with chronic brain ischemia and moderate cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/25726784
- Bellar et al (2015) The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650143/
- Parker et al (2015) The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595381/
- Stifler et al (2016) Targeting Mitochondrial Dysfunction with L-Alpha Glycerylphosphorylcholine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115775/
- Marcus et al (2017) Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629791/
- Alesenko et al (2017) Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers https://www.ncbi.nlm.nih.gov/m/pubmed/28745666/
- Alesenko et al (2017) Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers https://www.ncbi.nlm.nih.gov/pubmed/28745666
- Lee et al (2017) Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/27765578
- Gavrilova et al (2018) Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/29927403
- Barringer et al (2018) Impact of a purported nootropic supplementation on measures of mood, stress, and marksmanship performance in U.S. active duty soldiers https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984413/